Emily F. Conant1, Arijitt Borthakur1, Mitchell D. Schnall1, and Susan P. Weinstein1
1Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
Synopsis
We compare the scan and total study times from a newly
implemented abbreviated MR protocol (AP) for breast cancer screening consisting
of localizer, T2-STIR,
and single pair of pre- and post-contrast 3D T1 sequences to similar
times from our full MRI screening protocol.
A retrospective analysis was performed
using scan time data obtained from image dicom
files as well as data from the Radiology Information System (RIS) for technologist
activity
times to determine the variance between the two protocols. The results of this study will help guide operational
value improvements and estimates for appropriate pricing for the newly
implemented AP for breast cancer screening.
Objective
To compare
total study time as well as sub-components from a newly-implemented abbreviated protocol (AP) for MRI breast cancer screening with those from a full breast MRI screening protocol.Background
Mammography is the
only screening test which has been shown to reduce breast cancer mortality (1). However, the sensitivity of screening mammography
is known to be limited by increasing breast density due to masking of cancers
by dense breast tissue. In addition, increasing breast density is associated
with an increasing risk of developing breast cancer. Presently, over 50% of
U.S. states have implemented breast density legislation to notify women about
their individual breast density and the possible need for supplemental
screening to improve cancer detection–most often with whole breast ultrasound.
However, it is well known that breast MRI is more sensitive in detecting breast
cancers than mammography, ultrasound, or the combination of mammography and
ultrasound (2). Unfortunately,
standard breast MRI is expensive and therefore is currently limited to women
with a lifetime risk of >20%. Recently, an abbreviated protocol (AP) for MRI
breast cancer screening has been developed and has been shown to have excellent
sensitivity and specificity (3). With
significantly fewer imaging sequences, the AP is expected to increase patient
throughput and therefore significantly reduce imaging costs. Here we evaluate
the study times of our AP and compare it to our full MR protocol for breast
cancer screening. Methods
This
project was undertaken as a Quality Improvement Initiative and received
exemption by our Institutional Review Board.
A modification of the abbreviated protocol (AP) of Kuhl et al. (3) was implemented at our institution as a
supplemental screening study for women with mammographically dense breasts.
Currently, we include a T2 STIR sequence to investigate the added
diagnostic value, understanding that the T2 adds considerable time. For this analysis, we conducted a
retrospective study of a subset of patients who underwent contrast enhanced
breast MRI for breast cancer screening from September 2016-August 2017 with
either the abbreviated (N=70) or full (N=736) MRI protocols. Patients had either normal or benign
screening mammograms and for those undergoing the AP screen, their most recent
mammogram must have been reported as BI-RADS density b or c (heterogeneously or
extremely dense) (4). Statistical
analyses (ANOVA, Q-Q plots, etc.) were performed in JMP Pro 13 (SAS, Cary,
NC). We first calculated the total expected
scan time by summing the time of acquisition for each imaging series under
each protocol (Figure 1). Using code written in Python, the actual
scan time was obtained for each patient by calculating the difference
of the DICOM time stamps and recorded in a CSV file for analyses. Finally, the time from opening and closing a
patient exam by the tech was obtained by searching the RIS using mPower (Nuance
Inc, Burlington, MA) and was recorded as total study time. Subtracting actual scan time from total
scan time results in the total tech activity time, of which
there are scan-related activities
(processing MIPs, injecting) and non-scan-related activities e.g. removing patient.Results
On average the actual scan time for an AP screen was 17.5 mins which is
significantly faster than the full protocol time of 28.8 mins (difference = 11.3
mins; p<0.0001). Scan-related tech
activity time was ~5 minutes greater
for the AP screen and most likely due to image processing activities that can
be absorbed into the longer actual scan
time for the FULL screen. Additional
time measurement studies will be performed to fully explain this observation
and help guide operational efficiency improvements for AP scans. The AP screen has a 1.4x higher flow rate (1/total study time) because the FULL
screen’s non-scan related activity time was 72% more than the AP screen’s and could potential be reduced with lean
methods.Conclusions
Implementation
of the AP for breast cancer screening can significantly reduce scan times and
improve patient throughput. We recognize that the T2 sequence comprises
almost 50% of the expected scan time and may in the future be removed from the
protocol pending review of outcomes. Since
the AP screen is offered as a supplemental screen that currently is not
reimbursed by insurance, we will use this data and additional cost information to
estimate scheduling parameters, appropriate pricing and to target areas for
operational improvements. Acknowledgements
We thank Bruno Barufaldi, PhD, Thomas Chiang, and Donovan Reid for help with data extraction. This work was performed at a NIBIB Biomedical Technology Research Center under Grant No. P41 EB015893. References
- Tabár L, Vitak B, Chen TH, Yen AM, Cohen A,
Tot T, Chiu SY, Chen SL, Fann JC, Rosell J, Fohlin H, Smith RA, Duffy SW.
Swedish two-county trial: impact of mammographic screening on breast cancer
mortality during 3 decades. Radiology 2011;260(3):658-663.
-
Kuhl CK, Schrading S, Weigel S,
Nüssle-Kügele K, Sittek H, Arand B, Morakkabati N, Leutner C, Tombach B,
Nordhoff D, Perlet C, Rieber A, Heindel W, Brambs HJ, Schild H. [The
"EVA" Trial: Evaluation of the Efficacy of Diagnostic Methods (Mammography,
Ultrasound, MRI) in the secondary and tertiary prevention of familial breast
cancer. Preliminary results after the first half of the study period]. Rofo
2005;177(6):818-827.
-
Kuhl CK, Schrading S, Strobel K, Schild HH,
Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI):
first postcontrast subtracted images and maximum-intensity projection-a novel
approach to breast cancer screening with MRI. J Clin Oncol
2014;32(22):2304-2310.
- Sickles
E, D’Orsi C, Bassett L, et al. Mammography. In: ACR BI-RADS® Atlas,
Breast Imaging Reporting and Data System Reston, VA: American College of
Radiology; 2013.